These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12440407)

  • 21. Economic Evidence of Pneumococcal Vaccination in Older Adults: Uncertain Modelling or Competitive Tendering?
    Garattini L; Padula A; Da Costa MR
    Pharmacoeconomics; 2016 Mar; 34(3):221-4. PubMed ID: 26518294
    [No Abstract]   [Full Text] [Related]  

  • 22. Adults with invasive pneumococcal disease: missed opportunities for vaccination.
    Kyaw MH; Greene CM; Schaffner W; Ray SM; Shapiro M; Barrett NL; Gershman K; Craig AS; Roberson A; Zell ER; Schuchat A; Bennett NM; Whitney CG;
    Am J Prev Med; 2006 Oct; 31(4):286-92. PubMed ID: 16979452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).
    Isaacman DJ; Fletcher MA; Fritzell B; Ciuryla V; Schranz J
    Vaccine; 2007 Mar; 25(13):2420-7. PubMed ID: 17049677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).
    Beutels P; Thiry N; Van Damme P
    Vaccine; 2007 Feb; 25(8):1355-67. PubMed ID: 17208339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influenza and pneumococcal vaccination of the elderly in Taiwan.
    Chen YH; Liou SH; Chou CC; Su WL; Loh CH; Lin SH
    Vaccine; 2004 Jul; 22(21-22):2806-11. PubMed ID: 15246615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pneumococcal vaccine for all children].
    Paré R; Pilon PA
    Perspect Infirm; 2005; 2(5):30-1. PubMed ID: 15962532
    [No Abstract]   [Full Text] [Related]  

  • 27. Economic evaluation of pneumococcal conjugate vaccination in Finland.
    Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
    Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy.
    Merito M; Giorgi Rossi P; Mantovani J; Curtale F; Borgia P; Guasticchi G
    Vaccine; 2007 Jan; 25(3):458-65. PubMed ID: 17049685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
    Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB
    Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Introduction of pneumococcal vaccine to standard immunisation programmes in Europe: what are we waiting for?
    Heininger U
    Eur J Pediatr; 2002 Dec; 161 Suppl 2():S125-6. PubMed ID: 12494257
    [No Abstract]   [Full Text] [Related]  

  • 32. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
    Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR
    Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pneumococcal vaccination; arguments for informing parents about the options available].
    Beaujean DJ; Verweij MF; van Steenbergen JE
    Ned Tijdschr Geneeskd; 2005 Apr; 149(17):909-11. PubMed ID: 15884402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The economic cost of invasive pneumococcal disease and the potential for reduction by vaccination in an adult population in South Yorkshire.
    Parsons HK; Tomlin K; Metcalf SC; Brazier JE; Dockrell DH
    QJM; 2006 May; 99(5):348-9. PubMed ID: 16638754
    [No Abstract]   [Full Text] [Related]  

  • 36. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do Indian children need pneumococcal vaccination?
    Srivastava RN
    Indian Pediatr; 2007 Oct; 44(10):791; author reply 791-2. PubMed ID: 17998585
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of hospital vaccination programs in North Carolina.
    Honeycutt AA; Coleman MS; Anderson WL; Wirth KE
    Vaccine; 2007 Feb; 25(8):1484-96. PubMed ID: 17156901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Costs of pneumococcal infections and cost evaluation of heptavalent conjugate vaccine].
    D'Alessandro D
    Ann Ig; 2002; 14(6 Suppl 7):43-8. PubMed ID: 12638364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Commentary: Pneumococcal immunization may not be cost-effective in the elderly in developed countries.
    Waugh N
    Int J Epidemiol; 2005 Jun; 34(3):575-6. PubMed ID: 15764693
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.